AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small conductance calcium-activated potassium channel protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H2S1

UPID:

KCNN2_HUMAN

Alternative names:

KCa2.2

Alternative UPACC:

Q9H2S1; A6NF94; Q0VFZ4; Q6PJI0; Q6X2Y2

Background:

Small conductance calcium-activated potassium channel protein 2 (KCa2.2) plays a pivotal role in neuronal excitability regulation. It forms a voltage-independent potassium channel activated by intracellular calcium, leading to membrane hyperpolarization. This process is crucial for the slow component of synaptic afterhyperpolarization, influencing neuronal signaling.

Therapeutic significance:

KCa2.2 is implicated in Dystonia 34, myoclonic, and neurodevelopmental disorders with or without movement or behavioral abnormalities. These associations highlight its potential as a target for therapeutic intervention in neurological conditions characterized by involuntary muscle contractions, developmental delays, and intellectual disabilities.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.